Charles River Laboratories International, Inc and Rznomics Inc, a South Korea-based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, have established a viral vector contract development and manufacturing organization...
Charles River Laboratories International has launched a new AAV based platform that it claims has the capability to reduce time from process development to GMP by 55% and deliver a drug product in fewer than eight months.
Charles River recently announced the expansion of its plasmid DNA and viral vector development and manufacturing capabilities in Europe; it says the move is to support the growing need of customers and to safeguard future supply.
Charles River says the combination of Distributed Bio’s platform, which the CRO recently acquired, with its own downstream characterization capabilities, enables identification of the best lead candidate in CAR T cell therapies – balancing efficacy and...
Charles River says increased demand for biologics services prompted its recent Devon Park facility acquisition, bringing its Pennsylvania site count to three
Campaigning group People for the Ethical Treatment of Animals (PETA) picketed a conference in Boston on Tuesday to protest the use of animals in drug research and development.
Charles River says it is capitalising on the growing number of biologics in development, with its manufacturing business seeing double-digit growth led by demand for biosafety and cell banking services.
An expansion in Ireland for Eurofins, new cell screening tech for Cyprotex, and an mRNA development deal for Charles River. Welcome to Biopharma-Reporter’s bio-service round-up.
